These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23234810)

  • 1. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
    Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M
    Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early treatment: PreCISe-ly what the patient needs.
    Montalban X
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S2-6. PubMed ID: 20106344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
    Simon JH; Kinkel RP; Kollman C; O'Connor P; Fisher E; You X; Hyde R;
    Mult Scler; 2015 Apr; 21(4):415-22. PubMed ID: 25344370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
    Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
    Carter NJ; Keating GM
    Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.
    Swanton JK; Fernando KT; Dalton CM; Miszkiel KA; Altmann DR; Plant GT; Thompson AJ; Miller DH
    Mult Scler; 2010 Feb; 16(2):156-65. PubMed ID: 20086028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
    Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT
    Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
    Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
    Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.